Author

A. Gilmore

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

A. Carisey· 1 shared A. Eckersley· 1 shared A. M. McCorry· 1 shared A. Pitois· 1 shared B. Mambwe· 1 shared C. Ballestrem· 1 shared C. Courage· 1 shared C. Holohan· 1 shared

Activity by Year

2017-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

A. Carisey

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Novel in-silico predicted matrikines are differential mediators of in vitro and in vivo cellular metabolism

N. Jariwala, M. Ozols, A. Eckersley, B. Mambwe, R. E. B. Watson, L. Zeef, A. Gilmore, L. Debelle, M. Bell, E. J. Bradley, Y. Doush, C. Courage, R. Leroux, O. Peschard, P. Mondon, , M. J. Sherratt

The paper presents an in silico to in vivo pipeline to identify novel matrikines that differentially influence cellular metabolism in vitro and in vivo.

bioRxiv · Mar 17, 2023 · PreprintCell Biology

Force-independent interactions of talin and vinculin govern integrin-mediated mechanotransduction

P. Atherton, F. Lausecker, A. Carisey, A. Gilmore, D. Critchley, I. Barsukov, C. Ballestrem

This study shows that talin and vinculin interact without requiring force, challenging previous models of integrin-mediated mechanotransduction.

bioRxiv · May 7, 2019Cell Biology

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer

P. D. Dunne, H. G. Coleman, P. Bankhead, M. Alderdice, R. T. Gray, S. McQuaid, V. Bingham, M. B. Loughrey, J. A. James, A. M. McCorry, A. Gilmore, C. Holohan, D. Klingbiel, S. Tejpar, P. G. Johnston, , M. Lawler

The paper identifies Bcl-xL as a prognostic biomarker and predictor of response to adjuvant chemotherapy in BRAF-mutant stage II/III colon cancer using gene expression and immunohistochemistry validation.

bioRxiv · Oct 23, 2017Cancer Biology